Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (t-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: bimekizumab, m-1095 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 4 Parkinson's papers of 1,991 | 0.79 |
| pathways Reactome | 3 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 7002
Sealed predictions
- IL17F in dopamine neurons, braak+0.16 (p 0.680) → +0.27 (p 0.485)receipt 7009
Swarm cases
receipt 7009: IL17F in dopamine neurons, braak
- power
- full sample +0.24 (p 0.341, n 18), 95% CI -0.26 to +0.63. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.25 (p 0.319, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.22 (p 0.374, n 18). could be the mix.
- skeptic
- leave-one-out range +0.14 to +0.34, sign flips 0; without severely affected donors +0.24 (p 0.341, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IL17F in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts